



OPEN

Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers

Aya Sugiyama¹, Akemi Kurisu¹, Shintaro Nagashima¹, Kiyomi Hando¹, Khilola Saipova^{1,2}, Sayyora Akhmedova^{1,3}, Kanon Abe¹, Hirohito Imada¹, Md Razeen Ashraf Hussain¹, Serge Ouoba^{1,4}, Bunthen E^{1,5}, Ko Ko¹, Tomoyuki Akita¹, Shinichi Yamazaki⁶, Michiya Yokozaki⁶ & Junko Tanaka¹✉

Several factors related to anti-spike(S) IgG antibody titers after mRNA COVID-19 vaccination have been elucidated, but the magnitude of the effects of each factor has not been fully understood. This cross-sectional study assessed anti-S and anti-nucleocapsid (N) antibody titers on 3744 healthy volunteers (median age, 36 years; IQR, 24–49 years; females, 59.0%) who received two doses of mRNA-1273 or BNT162b2 vaccine and completed a survey questionnaire. Multiple regression was conducted to identify factors associated with antibody titers. All but one participant tested positive for anti-S antibodies (99.97%). The following factors were independently and significantly associated with high antibody titer: < 3 months from vaccination (ratio of means 4.41); mRNA-1273 vaccine (1.90, vs BNT162b2); anti-N antibody positivity (1.62); age (10's: 1.50, 20's: 1.37, 30's: 1.26, 40's: 1.16, 50's: 1.15, vs ≥60's); female (1.07); immunosuppressive therapy (0.54); current smoking (0.85); and current drinking (0.96). The largest impact on anti-S IgG antibody titers was found in elapsed time after vaccination, followed by vaccine brand, immunosuppressants, previous SARS-CoV-2 infection (anti-N antibody positive), and age. Although the influence of adverse reactions after the vaccine, gender, smoking, and drinking was relatively small, they were independently related factors.

In December 2019, an outbreak of pneumonia associated with severe acute respiratory coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China. It spread throughout the world in several weeks. The World Health Organization (WHO) declared on 11 March 2020 a global pandemic of the novel coronavirus disease (COVID-19). As of 31 March 2022, there were a total of 485,243,022 confirmed cases worldwide, including 6,137,553 deaths¹. In Japan, 6,538,890 confirmed cases have been reported, including 28,089 deaths². As a result of worldwide efforts, several COVID-19 vaccines began to roll out around the end of 2020. Between February and March 2021, Japanese drug authorities approved two messenger RNA (mRNA)-based vaccine products: BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna). It is reported that 79.5% of the Japanese population have

¹Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan. ²Department of Clinical Radiology and Oncology, Andijan State Medical Institute, Andijan, Uzbekistan. ³Department of Cardiorheumatology, Republican Specialized Scientific-Practical Medical Center of Pediatrics, Tashkent, Uzbekistan. ⁴Unité de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Science de La Santé (IRSS), Nanoro, Burkina Faso. ⁵Payment Certification Agency (PCA), Ministry of Health, Phnom Penh, Cambodia. ⁶Division of Clinical Laboratory Medicine, Hiroshima University Hospital, Hiroshima, Japan. ✉email: jun-tanaka@hiroshima-u.ac.jp

completed two doses of either vaccine at the time of writing³. These vaccines were reported to be approximately 95% effective in preventing COVID-19 infection^{4–6}.

Several factors related to antibody titers after mRNA COVID-19 vaccination have been elucidated, such as the time elapsed since the last vaccination^{7–13}, age^{14–16}, underlying conditions^{17–24}, history of SARS-CoV-2 infection^{25–30}, and vaccine brand³¹. It is reported that mRNA vaccines cause a high incidence of adverse reactions^{4,6,15,32,33}, but the relationship between adverse reactions and antibody responses has not yet reached a consensual conclusion^{14,16,34–36}. Although some possible factors are known to be related to antibody titers, analysis by adjusting potential confounders to clarify the magnitude of their effects is still needed.

We recruited a large cohort of healthy volunteers in Hiroshima, Japan, who received two mRNA vaccine doses and evaluated their serum antibody levels. The main purpose of this study was to investigate the clinical determinants of anti-spike protein (S) antibody titers following two doses of mRNA COVID-19 vaccine.

Methods

Study subjects. This was a large cross-sectional study of the general population conducted between August and September 2021. We identified a total of 21,406 individuals at Hiroshima University, consisting of 6059 staff members and 15,347 students. We sent them an e-mail asking for their willingness to undergo a serological test for anti-SARS-CoV-2 antibodies. Agreement and informed consent were obtained from 3915 persons, and their blood was collected to measure anti-SARS-CoV-2 antibody titers. In addition, a self-administered questionnaire survey was also conducted. The questionnaire had 17 items, including age, sex, other demographic factors, vaccination history, adverse reactions after vaccination, symptoms within the previous six months, personal infection prevention measures taken, history of COVID-19 infection or close contact with COVID-19 patients, social behavior patterns, comorbidities (hypertension, diabetes mellitus, heart disease, stroke, chronic obstructive lung disease, asthma, renal failure requiring dialysis, cancer, anemia, immunosuppression), smoking status, and drinking status. Overall, 3744 persons received two doses of mRNA-1273 or BNT162b2 vaccine and fully completed the questionnaire.

Laboratory assays. Venous blood samples (10 mL) were collected at the survey site and sent to the analytical laboratory at Hiroshima University the same day. Serum aliquots were prepared and stored at -20 degrees until serological analysis. Two U.S Food and Drug Administration (FDA) approved immunoassays were used to measure the titers of anti-spike protein (S) antibody immunoglobulin G (IgG) and anti-nucleocapsid protein (N) IgG.

VITROS Anti-SARS-CoV-2 S1 Quant IgG (Ortho Clinical Diagnostics; Rochester, NY, United States, sensitivity: 94.0%, specificity 100%³⁷) was used to detect Anti-S IgG on the VITROS 3600 Immunodiagnostic System (Ortho Clinical Diagnostics; Rochester, NY, United States). This chemiluminescent enzyme immunoassay targets the SARS-CoV-2 S protein, allowing the detection of antibodies due to vaccination or natural infection. The WHO standard binding antibody unit/mL (BAU/mL) was used, and ≥ 17.8 BAU/mL was defined as positive³⁸. The upper limit of measurement was 4000 BAU/mL.

SARS-CoV-2 N IgG was measured using the Elecsys Anti-SARS-CoV-2 (Roche Diagnostics International Ltd.; Rotkreuz, Switzerland, sensitivity: 99.5%, specificity 99.8%³⁹), a qualitative electrochemiluminescent immunoassay performed on the Cobas 8000 analyzer series e801 (Roche Diagnostics International Ltd.; Rotkreuz, Switzerland). This test returns a positive result (cutoff index ≥ 1.0) only in subjects with a history of natural infection.

All tests were performed in accordance with the manufacturers' instructions, and calibrations were inspected before analysis.

Ethics approval and consent to participate. The ethics committee for epidemiological research of Hiroshima University approved this study (approval number, E-2123-2). Informed consent was obtained from all participants before any study procedures. All study activities were performed in accordance with the Declaration of Helsinki and relevant guidelines and regulations in Japan.

Statistical analysis. Categorical variables are reported as numbers (percentages) and continuous variables as median and interquartile range (IQR). The Wilcoxon test was used to compare antibody titers in two groups, and the Kruskal–Wallis test was employed for more than two groups. Multivariate linear regression was used to assess associations between log-transformed IgG antibody titers and the following variables: gender, age, previous SARS-CoV-2 infection (defined as anti-N antibody positivity), vaccine brand, number of months since the second dose of vaccine, post-vaccination symptoms (severity was classified into three levels: away from work for more than two days, not away from work for more than two days, none), smoking status, drinking status, and presence of comorbidities. However, regarding comorbidities, heart disease, stroke, chronic obstructive lung disease, renal failure requiring dialysis, and cancer were found in less than 20 participants and were excluded from the analysis. Selected variables by stepwise procedure ($P < 0.25$) were used for multivariate analysis. All p -values were two-sided, and p -values < 0.05 were considered statistically significant. Data analysis was performed using JMP Pro 16.0 software (SAS Institute Inc., Cary, NC, USA).

Results

Characteristics of the participants. Among the 21,406 individuals who received our recruitment e-mail, 3915 agreed to participate (18.3%). Of these, 3744 had received two vaccine doses and completed the questionnaire fully (Fig. 1). Table 1 summarizes the demographic and background characteristics of the study participants. The median age was 36 years (IQR, 24–49 years), and females accounted for 59.0% of the participants. By vaccine brand, mRNA-1273 was more common (66.0%) than BNT162b2 (34.0%). The median number of days




Figure 1. Study population of vaccinated healthy volunteers.

from the second vaccination to blood collection was 37 (IQR, 29–60) (Supplementary Fig. S1). Due to post-vaccination adverse reactions, 18.6% had been away from work or school for more than two days, whereas 76.7% had adverse reactions but did not miss work or school for over two days, and 4.7% had no adverse reactions. The most common adverse reactions were severe injection site soreness (73.6%), fever (temperature ≥ 37.5 °C) (68.7%), fatigue (67.5%), headache (49.9%), and joint and muscle pain (47.3%).

Anti-S and anti-N IgG antibody titers. After two doses of BNT162b2 or mRNA-1273 vaccine, all recipients were positive for anti-S IgG except one person (3743/3744; 99.97%; 95% confidence interval (CI), 99.92–100%). Thirty-two participants also tested positive for anti-N IgG antibodies, suggesting previous SARS-CoV-2 infection (Table 2). Regarding the question “Were you infected with SARS-CoV-2 in the past?”, 9 of these 32 participants (28.1%) responded “yes”, 19 (59.4%) responded “no”, and 4 (12.5%) responded “I do not know”.

The participant who tested negative for both anti-S and anti-N antibodies was a male in his 60 s, with autoimmune disease, immunosuppressive therapy, hypertension, diabetes mellitus, chronic kidney disease, and a history of stroke. His blood was collected one month after receiving the second dose of the mRNA-1273 vaccine.

Anti-S IgG antibody titers. The median anti-S IgG antibody titer was 1750 BAU/mL (IQR, 651.3–3197.5). Supplementary Fig. S2 shows the distribution of anti-S IgG antibody titers by sex, age, anti-N antibody positivity, vaccine brand, time since the second dose, post-vaccination symptoms, smoking status, drinking status, and current history of hypertension, diabetes, anemia, asthma, immunosuppressive therapy, heart disease, cancer, and stroke.

Clinical determinants of anti-S IgG antibody titers after two vaccine doses. Multivariate linear regression identified the following factors as independently and significantly associated with anti-S IgG antibody titers after the second vaccine dose (Fig. 2): < 3 months after vaccination (ratio of means (RoM), 4.41; 95% CI 4.11–4.74); mRNA-1273 vaccine (vs. BNT162b2 vaccine; RoM, 1.90; 95% CI 1.79–2.02); anti-N antibody positivity (RoM, 1.62; 95% CI 1.31–2.00); age (reference group: ≥ 60 years; 10–19 years: RoM, 1.50; 95% CI 1.32–1.70; 20–29 years: RoM, 1.37; 95% CI 1.26–1.49; 30–39 years: RoM, 1.26; 95% CI 1.16–1.38; 40–49 years: RoM, 1.16; 95% CI 1.07–1.27; 50–59 years: RoM, 1.15; 95% CI 1.06–1.25); adverse reaction to vaccine (requiring ≥ 2 days leave from work or school vs. no adverse events: RoM, 1.25; 95% CI 1.12–1.38; not requiring for ≥ 2 days leave from work or school despite symptoms vs. no adverse events: RoM, 1.14, 95% CI 1.03–1.25); female sex (RoM, 1.07; 95% CI 0.13–1.12); current smoking (RoM, 0.85; 95% CI 0.78–0.94); current drinking (RoM, 0.96; 95% CI 0.92–1.00); and current immunosuppressive therapy (RoM, 0.54; 95% CI 0.43–0.69). Diabetes and anemia were not selected by the stepwise method.

Discussion

This cross-sectional study of a large cohort of healthy volunteers provided seroepidemiological data on anti-S IgG antibody titers and the factors that influenced them after two doses of mRNA-1273 or BNT162b2 vaccine. The major strength of this study is its large sample size which allowed for a reliable multivariate analysis. The most significant impact on anti-S IgG antibody titers after two doses of mRNA COVID-19 vaccine was found in elapsed time after vaccination, followed by vaccine brand, immunosuppressants, previous SARS-CoV-2 infection

Characteristic	N	%
Sex		
Female	2209	59.0
Male	1535	41.0
Age, median (IQR), year	36 (24–49)	
Age group, year		
10–19	147	3.9
20–29	1331	35.6
30–39	605	16.2
40–49	733	19.6
50–59	632	16.9
≥ 60	296	7.9
Previous SARS-CoV-2 infection^a		
Yes (anti-N antibody positive)	32	0.9
No (anti-N antibody negative)	3712	99.1
Vaccine brand		
mRNA-1273 (Moderna)	2470	66.0
BNT162b2 (Pfizer/BioNTech)	1274	34.0
Time since the second dose, day, median (IQR)	37 (29–60)	
Time since the second dose, month		
< 3	2896	77.4
≥ 3	848	22.7
Post-vaccination symptoms (any)		
Yes, away from work for more than 2 days	697	18.6
Yes, but not away from work for more than 2 days	2870	76.7
None	177	4.7
Post-vaccination symptoms		
Severe injection site soreness	2755	73.6
Fever (temperature ≥ 37.5 °C)	2571	68.7
Fatigue	2529	67.5
Headache	1867	49.9
Joint and muscle pain	1771	47.3
Nausea	289	7.7
Diarrhea	197	5.3
Skin rash	143	3.8
Current smoking		
Yes	162	4.3
No	3582	95.7
Current drinking		
Yes	1602	42.8
No	2142	57.2
Comorbidities		
Hypertension	218	5.8
Diabetes	57	1.5
Heart disease	13	0.3
Stroke	8	0.2
Chronic obstructive lung disease	3	0.1
Asthma	146	3.9
Renal failure requiring dialysis	2	0.1
Cancer	13	0.3
Anemia	57	1.5
Immunosuppression	24	0.6

Table 1. Demographic characteristics of the study participants (N = 3744). SAR-CoV-2 severe acute respiratory syndrome coronavirus 2. ^aPrevious SARS-CoV-2 infection was defined anti-SARS-CoV-2 Nucleocapsid (N) IgG antibody positivity.

	Anti-nucleocapsid (N) IgG		
	Negative	Positive	Total
Anti-spike (S) IgG*			
Negative	1 (0.03%)	0 (0.00%)	1 (0.03%)
Positive	3711 (99.12%)	32 (0.85%)	3743 (99.97%)
Total	3712 (99.15%)	32 (0.85%)	3744 (100%)

Table 2. Anti-Spike (S) IgG and anti-Nucleocapsid (N) IgG titers after 2 doses of mRNA-1273 or BNT162b2 COVID-19 vaccine in the general population (N = 3744). Anti-spike (S) IgG was measured using Vitros Anti-SARS-CoV-2 S1 Quant IgG (Ortho Clinical Diagnostics). Positive was defined as ≥ 17.8 binding antibody units/mL. Anti-nucleocapsid (N) IgG was measured using Elecsys Anti-SARS-CoV-2 (Roche Diagnostics International Ltd.). A positive result was defined as cutoff index ≥ 1.0 .




Figure 2. Multivariate linear regression results for anti-spike (S) protein IgG antibody titers after the second dose of mRNA COVID-19 vaccine. Model $P < 0.0001$, $R^2 = 0.7542$. *Comorbidities with fewer than 20 participants (heart disease, stroke, chronic obstructive lung disease, renal failure requiring dialysis, cancer) were excluded from the analysis. Variables were selected using the stepwise method ($P < 0.25$). SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, RoM ratios of means, CI confidence interval, IgG immunoglobulin G.

(anti-N antibody positive), and age. Although the influence of adverse reactions after the vaccine, gender, smoking, and drinking was relatively small, they were independently related factors. There have been many reports on post-vaccination antibody titers attenuation over time^{7-13,26,40}. The results of this study revealed that the elapsed time after vaccination most affected the anti-S IgG antibody titer after adjusting with other related factors. So far, no vaccinated person experienced anti-S IgG seroreversion after seven months of follow-up²⁶, but further long-term monitoring and research on the status of anti-SARS-CoV-2 antibodies is warranted.

After adjusting for other relevant factors, this study showed that the mean anti-S antibody titer was 1.9 times higher in those who received the mRNA-1273 vaccine (Moderna) compared to those who received the BNT162b2 vaccine (Pfizer/BioNTech). Previous studies have also demonstrated a significantly higher humoral immunogenicity and slower decay rate of antibody titer in those who received the mRNA-1273 vaccine compared with the BNT162b2 vaccine^{31,41,42}. There are two possible explanations for this difference. First, compared to the BNT162b2 vaccine, the mRNA-1273 vaccine has approximately three times the amount of mRNA material, resulting in higher antibody titers³¹. Second, there are some reports that the antibody titer is higher when the period between the first and the second dose is longer⁴³⁻⁴⁵. The interval between the first and second doses is one

week longer for the mRNA-1273 vaccine compared to the BNT162b2 vaccine (4 weeks vs. 3 weeks). On the other hand, the mRNA-1273 vaccine is also known to have a higher frequency of adverse reactions than BNT162b2³².

In general, vaccine-induced immunity is largely influenced by genetics, environmental factors, nutrition, sex, and the microbiome⁴⁶. Because of hormonal, genetic, and microbiota differences, females typically develop higher antibody titers and experience more adverse events following vaccination than males^{46,47}. Elderly individuals have lower antibody titers due to compromised T cell and plasma cell function^{14–17,48}. Our study also showed that female sex and young age are both predictors of stronger antibody responses, but the impact of sex was relatively small. Unfortunately, this study could not examine people over 75 years, and further studies are required to address this age group. As for immunosuppressive therapy, it was significantly associated with lower antibody titers, as in previous reports^{18,19,22–24,49}, because patients with immunosuppression have poor humoral and cellular immune responses⁴⁹.

In this study, current smoking and current drinking were associated with lower antibody titers. These findings were consistent with previous studies^{50,51}, suggesting that these lifestyle habits compromise immune function.

In individuals with normal immune function, SARS-CoV-2 infection induces SARS-CoV-2-specific memory cells, which produce anti-S antibodies up to 6 months after infection⁵². Post-vaccination anti-S IgG antibody titers are higher in patients with a history of natural infection than those without^{25,27–30,53}. Our study also showed that previous SARS-CoV-2 infection is significantly associated with higher antibody levels.

Adverse reactions after mRNA-based COVID-19 vaccination are common^{4,6,15,32,33}. Previous study results were inconsistent regarding the association between adverse reactions and antibody titers^{14,34–36,54}. We found a tendency for anti-S IgG antibody titers to be high when adverse reactions were severe, but the impact was relatively small after adjusting for multiple confounding factors. The causal relationship between adverse reactions after mRNA-based COVID-19 vaccination and antibody reactions has not been fully elucidated. Type I interferon, multiple pro-inflammatory cytokines, and chemokines produced by the booster vaccine, which induce injection-site and systemic inflammation (side effects), are supposed to promote an antibody-producing immune response⁵⁵. However, all study participants who did not experience adverse reactions still acquired anti-S antibodies, suggesting that the absence of adverse reactions does not rule out immunogenicity. This finding supports the need to improve vaccine safety and reduce the rate of adverse reactions.

During the study period (August–September 2021), Hiroshima Prefecture was in the midst of the fifth epidemic wave of infections with the alpha and delta variants. COVID-19 cases confirmed by the end of August 2021 accounted for 0.67% of the total population in Hiroshima (approximately 2.8 million)⁵⁶. Elevated anti-N IgG titers are a hallmark of past natural SARS-CoV-2 infection. We determined that 0.85% of study participants had a history of SARS-CoV-2 infection, as evidenced by anti-N IgG testing. Among them, 71.9% were not aware of a previous infection. Since asymptomatic patients accounted for 16–33.3% of COVID-19 patients in previous studies^{57–59}, there was a much higher prevalence of asymptomatic SARS-CoV-2 infection in this study. This might be partly attributable to our study participants being relatively young (median age, 36 years). Also, although the anti-N IgG testing is highly specific, false positive results due to nonspecific reactions may be possible because this study was conducted in a population with a very low prevalence of past infections^{39,60}.

Our study has several limitations. First, the study participants consisted of staff members and students of the university community. This population could have been skewed towards the healthier and younger ends of the general population. Our study did not include individuals aged 75 years or older because of the retirement age regulations; further investigations in this age group are warranted. The results of this study should be interpreted as representative of the healthy general population, and the characterization of post-vaccination antibodies in populations with specific comorbidities should be revealed by other studies. In addition, study participants were mostly individuals of Japanese origin, which did not allow for comparisons by race or ethnicity. Second, comorbidities and adverse reactions were self-reported by participants and could be a source of recall bias and underestimation. Third, this study did not investigate the effects of neutralizing antibodies and T-cell responses. Even though a strong correlation has been reported between neutralizing antibody titers and IgG titers^{17,40,61,62}, the relationship between antibody titers and the clinical protection potential of vaccines, as well as their effects on new variants, is not sufficiently clear.

Conclusions

This study clarified factors influencing anti-S IgG antibody titers after two mRNA vaccine doses based on a large set of seroepidemiological data. The results of this study may serve as a reference for the third and subsequent vaccine policy developments in a general population: the people who should be most prioritized for the third vaccination are those with a long time since the second vaccination. Priority should then be given to those who received BNT162b2 vaccine instead of mRNA-1273, followed by those on immunosuppressants, those without past infection (including asymptomatic infections), and people aged 60 years or older. Finally, the booster dose should also be advised to people who had no adverse reactions after vaccination, males, smokers, and alcohol consumers.

Data availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Received: 15 April 2022; Accepted: 19 September 2022

Published online: 29 September 2022

References

- World Health Organization WHO. Available at: <https://covid19.who.int/>. Accessed 15 Feb 2022.
- Ministry of Health, Labour and Welfare Japan. Available at: <https://covid19.mhlw.go.jp/>. Accessed 15 Feb 2022.
- Prime Minister's Office Japan. Available at: <https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html>. Accessed 15 Feb 2022.
- Polack, F. P. *et al.* Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).
- Pfizer-BioNTech. Pfizer-BioNTech COVID-19 Vaccine (BNT162, PF-07302048). Vaccines and Related Biological Products Advisory Committee Briefing Document. Available at: <https://www.fda.gov/media/144246/download>.
- Baden, L. R. *et al.* Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N. Engl. J. Med.* **384**, 403–416 (2021).
- Favresse, J. *et al.* Antibody titres decline 3-month post-vaccination with BNT162b2. *Emerg. Microbes Infect.* **10**, 1495–1498 (2021).
- Tretny, A. *et al.* Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination. *Cells* **10**, 1 (2021).
- Harris, R. J. *et al.* Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. *J. Infect.* **82**, 162–169 (2021).
- Wheeler, S. E. *et al.* Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. *Microbiol. Spectr.* **9**, e0034121 (2021).
- Wisniewski, A. V., Campillo Luna, J. & Redlich, C. A. Human IgG and IgA responses to COVID-19 mRNA vaccines. *PLoS ONE* **16**, e0249499 (2021).
- Naaber, P. *et al.* Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. *Lancet Reg. Health Eur.* **10**, 100208 (2021).
- Danese, E. *et al.* Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: A three-case series. *Clin. Chem. Lab. Med.* **59**, 1585–1591 (2021).
- Coggins, S. A. A. *et al.* Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. *medRxiv* **1**, 1 (2021).
- Walsh, E. E. *et al.* Safety and immunogenicity of Two RNA-based covid-19 vaccine candidates. *N. Engl. J. Med.* **383**, 2439–2450 (2020).
- Müller, L. *et al.* Age-dependent immune response to the Biontech/Pfizer BNT162b2 Coronavirus disease 2019 vaccination. *Clin. Infect. Dis.* **73**, 2065–2072 (2021).
- Lustig, Y. *et al.* BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: A prospective, single-centre, longitudinal cohort study in health-care workers. *Lancet Respir. Med.* **9**, 999–1009 (2021).
- Boyarsky, B. J. *et al.* Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. *JAMA* **325**, 2204–2206 (2021).
- Grupper, A. *et al.* Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. *Am. J. Transplant* **21**, 2719–2726 (2021).
- Rabinowich, L. *et al.* Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. *J. Hepatol.* **75**, 435–438 (2021).
- Deepak, P. *et al.* Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. *medRxiv* **1**, 1 (2021).
- Rincon-Arevalo, H. *et al.* Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. *Sci. Immunol.* **6**, 1 (2021).
- Sattler, A. *et al.* Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. *J. Clin. Invest.* **131**, 1 (2021).
- Tenforde, M. W. *et al.* Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. *Clin. Infect. Dis.* **1**, 1 (2021).
- Kontopoulou, K. *et al.* Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: Real-world evidence from Greek healthcare workers. *J. Med. Microbiol.* **70**, 1 (2021).
- Olariu, T. R., Ursoniu, S., Marincu, I. & Lupu, M. A. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine: A 7-month follow-up study. *Medicina* **1**, 57 (2021).
- Ebinger, J. E. *et al.* Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat. Med.* **27**, 981–984 (2021).
- Krammer, F. *et al.* Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. *N. Engl. J. Med.* **384**, 1372–1374 (2021).
- Prendecki, M. *et al.* Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. *Lancet* **397**, 1178–1181 (2021).
- Blain, H. *et al.* Spike antibody levels of nursing home residents with or without prior COVID-19 3 weeks after a single BNT162b2 vaccine dose. *JAMA* **1**, 1 (2021).
- Montoya, J. G. *et al.* Differences in IgG antibody responses following BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines. *Microbiol. Spectr.* **9**, e0116221 (2021).
- Kitagawa, H. *et al.* Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. *J. Infect. Chemother.* **1**, 1 (2022).
- Jackson, L. A. *et al.* An mRNA vaccine against SARS-CoV-2—preliminary report. *N. Engl. J. Med.* **383**, 1920–1931 (2020).
- Takeuchi, M., Higa, Y., Esaki, A., Nabeshima, Y. & Nakazono, A. Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?. *PLoS ONE* **16**, e0257668 (2021).
- Tani, N. *et al.* Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine. *Vaccine* **40**, 2062–2067 (2022).
- Uwamino, Y. *et al.* Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff. *Vaccine* **40**, 1019–1025 (2022).
- Ortho Clinical Diagnostics. VITROS Anti-SARS-CoV-2 S1 Quant IgG reagent pack. 2021.
- World Health Organization WHO. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. 2020. WHO Expert Committee on Biological Standardization. Available at: https://cdn.who.int/media/docs/default-source/biologicals/ecbs/bs-2020-2403-sars-cov-2-ab-ik-17-nov-2020_4ef4fdae-e1ce-4ba7-b21a-d725c68b152b.pdf?sfvrsn=662b46ae_8&download=true.
- Roche Diagnostics. Available at: <https://diagnostics.roche.com/jp/ja/products/params/electsys-anti-sars-cov-2.html>.
- Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639–644 (2021).
- Keshavarz, B. *et al.* Trajectory of IgG to SARS-CoV-2 after vaccination with BNT162b2 or mRNA-1273 in an employee cohort and comparison with natural infection. *Front. Immunol.* **13**, 850987 (2022).
- Steensels, D., Pierlet, N., Penders, J., Mesotten, D. & Heylen, L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. *JAMA* **326**, 1533–1535 (2021).
- Voysey, M. *et al.* Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881–891 (2021).

44. Payne, R. P. *et al.* Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell* **184**, 5699–714. e11 (2021).
45. Hall, V. G. *et al.* Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. *Nat. Immunol.* **23**, 380–385 (2022).
46. Fischinger, S., Boudreau, C. M., Butler, A. L., Streeck, H. & Alter, G. Sex differences in vaccine-induced humoral immunity. *Semin. Immunopathol.* **41**, 239–249 (2019).
47. Klein, S. L., Marriott, I. & Fish, E. N. Sex-based differences in immune function and responses to vaccination. *Trans. R Soc. Trop. Med. Hyg.* **109**, 9–15 (2015).
48. Gustafson, C. E., Kim, C., Weyand, C. M. & Goronzy, J. J. Influence of immune aging on vaccine responses. *J. Allergy Clin. Immunol.* **145**, 1309–1321 (2020).
49. Collier, A. Y. *et al.* COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals. *J. Infect. Dis.* **1**, 1 (2021).
50. Watanabe, M. *et al.* Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. *Diabetes Metab. Res. Rev.* **38**, e3465 (2022).
51. Kageyama, T. *et al.* Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. *Clin. Microbiol. Infect.* **27**, 1861 (2021).
52. L'Huillier, A. G. *et al.* Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: A prospective longitudinal study. *Clin. Microbiol. Infect.* **1**, 1 (2021).
53. Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* **1**, 371 (2021).
54. Yamamoto, S. *et al.* Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine. *Vaccine* **40**, 1924–1927 (2022).
55. Teijaro, J. R. & Farber, D. L. COVID-19 vaccines: modes of immune activation and future challenges. *Nat. Rev. Immunol.* **21**, 195–197 (2021).
56. Hiroshima Prefectural Government's official site. Available at: <https://www.pref.hiroshima.lg.jp/site/2019-ncov/>. Accessed 13 Sep 2021.
57. He, J., Guo, Y., Mao, R. & Zhang, J. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. *J. Med. Virol.* **93**, 820–830 (2021).
58. National institution of infectious diseases Japan. National Institute of Infectious Diseases. Field Briefing: diamond Princess COVID-19 cases (2020).
59. Nishiura, H. *et al.* Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int. J. Infect. Dis.* **94**, 154–155 (2020).
60. Sugiyama, A. *et al.* A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020. *Environ. Health Prev. Med.* **27**, 30 (2022).
61. Wajnberg, A. *et al.* Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* **370**, 1227–1230 (2020).
62. Seow, J. *et al.* Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat. Microbiol.* **5**, 1598–1607 (2020).

Acknowledgements

We thank the students and employees of Hiroshima University and Hiroshima University Hospital for their participation in the study. We thank the General Affairs Group of Hiroshima University for their support of this survey.

Author contributions

Study concept and design: J.T. Acquisition of data: A.S., K.H., K.S., S.A., K.A., R.A., S.O., B.E., and J.T. Immunoassays: K.H., K.S., S.A., K.A., H.I., R.A., S.O., B.E., K.K., S.N., S.Y., and M.Y. Data management: A.K. and J.T. Data analysis: A.S., A.K., T.A., and J.T. Statistical analysis: A.S., T.A., and J.T. Interpretation of data: A.S., T.A., and J.T. Manuscript development: A.S., R.A., S.O., B.E., T.A., and J.T. Study supervision: J.T. All authors reviewed and approved the final version of the manuscript.

Funding

This research was supported by the Japan Agency for Medical Research and Development (AMED) under grant number JP20fk0108453 and JP21fk0108550. The funder had no role in the study design, data collection, analysis, interpretation, or manuscript preparation.

Competing interests

Measurement of antibody by using reagents of Ortho Clinical Diagnostics was technically supported by Ortho Clinical Diagnostics. Professor Junko Tanaka received speaker's fees from Ortho Clinical Diagnostics. The other authors have no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-20747-x>.

Correspondence and requests for materials should be addressed to J.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022, corrected publication 2023